Arimoclomol, which boosts the chaperone response, slows the progression of Niemann-Pick disease type C (phase 2/3); FDA-approved in 2024.
Confidence
Established
Level of evidence
●●●●●● Approved by a health authority
Observed in
Human
Mission
Map of aging (12 hallmarks)
Concepts
Loss of proteostasisArimoclomolNiemann-Pick disease type CMolecular chaperones (HSP70, HSP90)
What the sources say
Each row is an article. “Supports”: it backs the claim. “Contradicts”: it goes against it. “Qualifies”: it limits it (another species, a weaker effect…).